Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of "Buy" from Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have been given a consensus recommendation of "Buy" by the eight brokerages that are currently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $52.11.

Several research firms recently commented on MIRM. Raymond James reduced their price target on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a "strong-buy" rating on the stock in a research note on Tuesday, December 19th. HC Wainwright reaffirmed a "buy" rating and set a $58.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 2nd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $35.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. JMP Securities raised their price objective on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday, March 14th. Finally, SVB Leerink lowered their target price on Mirum Pharmaceuticals from $44.00 to $43.00 and set an "outperform" rating for the company in a report on Monday, March 18th.

Insider Activity

In related news, CFO Eric Bjerkholt acquired 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average cost of $25.80 per share, for a total transaction of $51,600.00. Following the purchase, the chief financial officer now directly owns 12,000 shares of the company's stock, valued at approximately $309,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Peter Radovich sold 4,303 shares of the firm's stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the sale, the chief operating officer now directly owns 29,013 shares in the company, valued at approximately $748,535.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Eric Bjerkholt acquired 2,000 shares of the business's stock in a transaction dated Monday, March 18th. The stock was purchased at an average cost of $25.80 per share, for a total transaction of $51,600.00. Following the transaction, the chief financial officer now owns 12,000 shares in the company, valued at $309,600. The disclosure for this purchase can be found here. Company insiders own 24.06% of the company's stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Silverarc Capital Management LLC increased its position in shares of Mirum Pharmaceuticals by 0.4% during the second quarter. Silverarc Capital Management LLC now owns 106,375 shares of the company's stock worth $2,752,000 after purchasing an additional 436 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Mirum Pharmaceuticals by 98.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company's stock valued at $31,000 after buying an additional 488 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in Mirum Pharmaceuticals by 1.2% in the third quarter. Los Angeles Capital Management LLC now owns 42,444 shares of the company's stock worth $1,341,000 after acquiring an additional 494 shares in the last quarter. Royal Bank of Canada boosted its holdings in Mirum Pharmaceuticals by 40.1% in the second quarter. Royal Bank of Canada now owns 1,851 shares of the company's stock worth $48,000 after acquiring an additional 530 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 4.9% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,037 shares of the company's stock worth $358,000 after acquiring an additional 654 shares during the last quarter.

Mirum Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ:MIRM traded up $0.28 during trading hours on Tuesday, hitting $26.20. 402,532 shares of the company's stock traded hands, compared to its average volume of 590,521. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.45 and a quick ratio of 4.19. The business has a fifty day moving average price of $27.29 and a 200-day moving average price of $28.84. Mirum Pharmaceuticals has a 1 year low of $22.34 and a 1 year high of $35.56. The firm has a market capitalization of $1.23 billion, a P/E ratio of -6.53 and a beta of 1.14.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.32). The business had revenue of $69.55 million for the quarter, compared to analysts' expectations of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. Equities analysts expect that Mirum Pharmaceuticals will post -1.12 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.